Search clinical trials for: Xarelto

Total 242 results

Jilin University

Recruiting

Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction (ACTonLVT)

ST-segment Elevation Myocardial Infarction (STEMI) | Left Ventricular Thrombus

China
Ottawa Heart Institute Research Corporation

Recruiting

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Radial Artery Occlusion

Canada
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)

Myocardial Infarction | Ischemic Stroke | Atrial Fibrillation | All-cause Mortality | Systemic Embolization | Major Bleed

Canada
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

Coronary Artery Disease | Cardiovascular Disease

Belgium, Netherlands
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Eli Lilly and Company

Completed

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

Healthy

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis

Mild Cognitive Impairment

China
Novartis Pharmaceuticals

Completed

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Aplastic Anemia

Japan
China-Japan Friendship Hospital

Not yet recruiting

Effectiveness and Safety of Rivaroxaban Used in Extended Anticoagulation for Pulmonary Embolism Patients

Pulmonary Embolism
Assistance Publique - Hôpitaux de Paris

Completed

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. (RIPORT)

Deep Vein Thrombosis | Chronic Portal Vein Thrombosis

France
Insel Gruppe AG, University Hospital Bern

Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (ELAN)

Ischaemic Stroke

Belgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
Seoul National University Hospital
Korean Society of Hematology Thrombosis Working Party

Completed

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Recurrence | Bleeding | Cancer-associated Thrombosis | Rivaroxaban

Korea, Republic of
London Health Sciences Centre

Completed

Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)

Central Venous Catheter Thrombosis | Neoplasm

Canada
Azienda Ospedaliero, Universitaria Ospedali Riuniti

Recruiting

Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population

Intracardiac Thrombus

Italy
Genuine Research Center, Egypt
Horus for Pharmaceutical Industries, Egypt

Completed

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

Healthy

Egypt
Ostfold Hospital Trust

Completed

Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study (Ri-Schedule)

Deep Venous Thrombosis

Norway
University of Padova

Completed

Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy (ERIKA)

Venous Thromboembolism | Haemorrhage

Italy
St. Joseph's Healthcare Hamilton
Bayer; University of Alberta; The Ottawa Hospital; Hamilton Health Sciences Corporation and other collaborators

Completed

Rivaroxaban for Antiphospholipid Antibody Syndrome (RAPS)

Antiphospholipid Antibody Syndrome

Canada
State University of New York - Upstate Medical...

Terminated

Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery

Gastric Bypass Status

United States
Hospital Ana Nery
Federal University of Bahia

No longer available

Rivaroxaban in Mechanical Valves: RMV Study (RMV)

Prosthesis; Cardiac, Heart, Functional Disturbance as Result
University of Padova

Terminated

Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS)

Antiphospholipid Syndrome

Italy
Kyunghee University Medical Center

Unknown

Pleotropic Effect of New Oral Anticoagulants

Atrial Fibrillation

Korea, Republic of
Sherief Abd-Elsalam

Unknown

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Portal Vein Thrombosis

Egypt
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effect of Rivaroxaban in Sickle Cell Disease

Sickle Cell Anemia | Sickle Cell-Beta0-Thalassemia

United States
Hospital Universitari Vall d'Hebron Research Institute

Completed

Rivaroxaban for Patients With Antiphospholipid Syndrome

Antiphospholipid Syndrome

Spain
Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Hospital Alemão Oswaldo Cruz
Bayer; Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Brazilian... and other collaborators

Terminated

COVID-19 Antithrombotic Rivaroxaban Evaluation (CARE)

COVID-19

Brazil
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)

Atrial Fibrillation

Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
Bayer
Janssen Research & Development, LLC; RTI Health Solutions

Completed

Patient and Physician Knowledge of Key Safety Messages

Anticoagulation

Germany, United Kingdom, France, Spain
Bayer
Janssen Research & Development, LLC

Completed

A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants

Thromboembolic Disorders

Germany
Bayer
Janssen Research & Development, LLC

Completed

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

Thrombosis

Canada, United States, Belgium, Spain, Italy, France, Finland, Hungary
Bayer
Janssen Research & Development, LLC

Completed

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Venous Thromboembolism

United States
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis (EINSTEINJr)

Venous Thromboembolism

Switzerland, Spain, United States, Austria, Italy, Russian Federation, United Kingdom, Brazil, Australia, Canada, Hungary, Netherlands, Israel, Poland, Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (XANAP)

Atrial Fibrillation

Indonesia, Korea, Republic of, Malaysia, Singapore, Thailand, Philippines, Taiwan, Hong Kong, India, Pakistan, Vietnam
Bayer
Janssen Research & Development, LLC

Completed

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (HEROIC)

Atrial Fibrillation

Spain
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)

Venous Thrombosis

Belgium
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Venous Thrombosis | Pediatrics

Italy, United States, Austria, Australia, Canada, France, Switzerland, Germany, Israel, Ireland
University of North Carolina, Chapel Hill

Completed

A Prospective Pharmacodynamic Study of Rivaroxaban

Blood Clot

United States
Bayer
Janssen Research & Development, LLC

Not yet recruiting

An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure

Children | Congenital Heart Disease | Prevention of Venous Thromboembolism | Fontan Procedure

Japan
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism...

Recruiting

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (COBRRA)

Venous Thromboembolism

Canada
Bayer
Janssen Research & Development, LLC

Completed

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function (XARETO)

Non-valvular Atrial Fibrillation (NVAF)

Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (EMIR)

Atrial Fibrillation

Spain
Brigham and Women's Hospital

Completed

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto [SPAF] Post-marketing Surveillance in Japan

Brain Ischemia

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (XaMINA)

Atrial Fibrillation

Korea, Republic of, Taiwan
Hospital do Servidor Publico Estadual

Unknown

Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs. (DVT)

Deep Venous Thrombosis

Brazil
Bayer
Janssen Research & Development, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication (SATORI)

Venous Thrombosis

France
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)

Atrial Fibrillation

Belgium
McMaster University

Terminated

Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

Heparin-induced Thrombocytopenia

Canada

Search clinical trials for: Xarelto

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations